There are two different phase 3 trials ongoing right now. They should complete during 2017. I don't forsee any problems getting the NDA approved by the FDA. However, that will likely not be until 2018. Keep in mind that this will be approved as a secondary, recovery drug. It won't be indicted or available for primary treatment.